Seres Therapeutics Inc (NASDAQ:MCRB) insider David N. Cook sold 1,738 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $11.02, for a total transaction of $19,152.76. Following the completion of the transaction, the insider now owns 141,673 shares in the company, valued at $1,561,236.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Seres Therapeutics Inc (MCRB) opened at $10.42 on Wednesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. Seres Therapeutics Inc has a twelve month low of $8.85 and a twelve month high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $17.29 million. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The company’s revenue for the quarter was up 76.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.46) EPS. analysts forecast that Seres Therapeutics Inc will post -2.33 EPS for the current year.
A number of analysts recently weighed in on MCRB shares. Seaport Global Securities reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a report on Friday, October 6th. Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Citigroup started coverage on shares of Seres Therapeutics in a report on Thursday, October 12th. They issued a “positive” rating and a $19.00 price objective on the stock. CIBC started coverage on shares of Seres Therapeutics in a report on Friday, October 13th. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Oppenheimer started coverage on shares of Seres Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $19.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $18.00.
A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Seres Therapeutics by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock valued at $17,911,000 after buying an additional 19,363 shares during the period. Ark Investment Management LLC increased its stake in Seres Therapeutics by 21.5% during the 2nd quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock valued at $8,647,000 after buying an additional 135,276 shares during the period. JPMorgan Chase & Co. increased its stake in Seres Therapeutics by 39.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after buying an additional 106,479 shares during the period. State Street Corp increased its stake in Seres Therapeutics by 12.0% during the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after buying an additional 34,393 shares during the period. Finally, Northern Trust Corp increased its stake in Seres Therapeutics by 16.2% during the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after buying an additional 32,875 shares during the period. 75.83% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Seres Therapeutics Inc (MCRB) Insider David N. Cook Sells 1,738 Shares” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/31/seres-therapeutics-inc-mcrb-insider-david-n-cook-sells-1738-shares.html.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.